Heparinized chitosan/poly(γ-glutamic acid) nanoparticles for multi-functional delivery of fibroblast growth factor and heparin

Biomaterials

Volumn 31, Issue 35, 2010, Pages 9320-9332

  Tang, Deh Wei ^a   Yu, Shu Huei ^a   Ho, Yi Cheng ^a   Mi, Fwu Long ^a   Kuo, Pi Li ^a   Sung, Hsing Wen ^b  

^a VANUNG UNIVERSITY   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

PGA; BFGF; Chitosan; Heparin functionalized; Nanoparticles

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BFGF; BLOOD PLASMA; BLOOD SUPPLY; FACTOR XA; FIBROBLAST CELLS; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR (BFGF); FUNCTIONALIZED; GLUTAMIC ACID; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; ISCHEMIC INJURIES; ISCHEMIC TISSUES; LOADING EFFICIENCY; MEAN PARTICLE SIZE; MITOGENIC ACTIVITY; MULTI-FUNCTIONAL; NANOCARRIERS; PH SENSITIVE; PH VALUE; SUSTAINED RELEASE; THERAPEUTIC ANGIOGENESIS; THERAPEUTIC METHOD; TUBE FORMATION; VESSEL FORMATION;

AMINO ACIDS; BLOOD; BLOOD VESSELS; CELL CULTURE; CHITIN; CHITOSAN; DRUG PRODUCTS; ENDOTHELIAL CELLS; FIBROBLASTS; PEPTIDES; POLYSACCHARIDES;

NANOPARTICLES;

CHITOSAN; HEPARIN; NANOPARTICLE; POLY(GAMMA GLUTAMIC ACID); RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTICOAGULATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FIBROBLAST; HEPARINIZATION; HUMAN; HUMAN CELL; ISCHEMIA; MITOGENESIS; NORMAL HUMAN; PARTICLE SIZE; PH; PREPUCE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; THROMBOSIS PREVENTION; TISSUE REGENERATION; TISSUE REPAIR; UMBILICAL VEIN;

ANTICOAGULANTS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHITOSAN; CIRCULAR DICHROISM; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HEPARIN; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, PHASE-CONTRAST; NANOPARTICLES; POLYGLUTAMIC ACID;

EID: 77957949816     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.08.058     Document Type: Article

References (46)

1. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
2. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., et al. Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
3. Peng S.F., Su C.J., Wei M.C., Chen C.Y., Liao Z.X., Lee P.W., et al. Effects of the nanostructure of dendrimer/DNA complexes on their endocytosis and gene expression. Biomaterials 2010, 31:5660-5670.
4. Murphy E.A., Majeti B.K., Barnes L.A., Makale M., Weis S.M., Lutu-Fuga K., et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. PNAS 2008, 105:9343-9348.
5. Lo K.H., Chen M.C., Ho R.M., Sung H.W. Pore-filling nanoporous templates from degradable block copolymers for nanoscale drug delivery. ACS Nano 2009, 3:2660-2666.
6. Chung T.W., Wang S.S., Tsai W.J. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly(lactide-co-glycolide) (PLGA) nanoparticles. Biomaterials 2008, 29:228-237.
7. Liang H.F., Chen S.C., Chen M.C., Lee P.W., Chen C.T., Sung H.W. Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system against cultured HepG2 cells. Bioconjug Chem 2006, 17:291-299.
8. Chiu Y.L., Ho Y.C., Chen Y.M., Peng S.F., Ke C.J., Chen K.J., et al. The characteristics, cellular uptake and intracellular trafficking of nanoparticles made of hydrophobically-modified chitosan. J Control Release 2010, 10.1016/j. jconrel.2010.05.023.
9. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharmacol 2008, 5:496-504.
10. Lin Y.H., Mi F.L., Chen C.T., Chang W.C., Peng S.F., Liang H.F., et al. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 2007, 8:146-152.
11. Lin Y.H., Sonaje K., Lin K.M., Juang J.H., Mi F.L., Yang H.W., et al. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J Control Release 2008, 132:141-149.
12. Mi F.L., Wu Y.Y., Lin Y.H., Sonaje K., Ho Y.C., Chen C.T., et al. Nanoparticles self-assembled by N-trimethylchitosan and poly(γ-glutamic acid) for oral delivery of protein drugs. Bioconjug Chem 2008, 19:1248-1255.
13. Sonaje K., Chen Y.J., Chen H.L., Wey S.P., Juang J.H., Nguyen H.N., et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 2010, 31:3384-3394.
14. Lee P.W., Peng S.F., Su C.J., Mi F.L., Chen H.L., Wei M.C., et al. The use of biodegradable polymeric nanoparticles in combination with a low-pressure gene gun for transdermal DNA delivery. Biomaterials 2008, 29:742-751.
15. Peng S.F., Yang M.J., Su C.J., Chen H.L., Lee P.W., Wei M.C., et al. Effects of incorporation of poly(gamma-glutamic acid) in chitosan/DNA complex nanoparticles on cellular uptake and transfection efficiency. Biomaterials 2009, 30:1797-1808.
16. Lee P.W., Hsu S.H., Tsai J.S., Chen F.R., Huang P.J., Ke C.J., et al. Multifunctional core-shell polymeric nanoparticles for transdermal DNA delivery and epidermal Langerhans cells tracking. Biomaterials 2010, 31:2425-2434.
17. Rapraeger A.C., Krufka A., Olwin B.B. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991, 252:1705-1708.
18. Yanagisawa-Miwa A., Uchida Y., Nakamura F., Tomaru T., Kido H., Kamijo T., et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992, 257:1401-1403.
19. Layman H., Sacasa M., Murphy A.E., Murphy A.M., Pham S.M., Andreopoulos F.M. Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model. Acta Biomaterialia 2009, 5:230-239.
20. Chung Y.I., Tae G., Yuk S.H. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors. Biomaterials 2006, 27:2621-2626.
21. Nillesen S.T.M., Geutjes P.J., Wismans R., Schalkwijk J., Daamen W.F., van Kuppevelt T.H. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 2007, 28:1123-1131.
22. Ruoslahti E., Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991, 64:867-869.
23. Chang Y., Lai P.H., Wei H.J., Lin W.W., Chen S.C., Sung H.W., et al. Tissue regeneration observed in a basic fibroblast growth factor-loaded porous acellular bovine pericardium populated with mesenchymal stem cells. J Thorac Cardiovasc Surg 2007, 134:65-73.
24. Sutherland S.P., Benson C.J., Adelman J.P., McCleskey E.W. From the Cover: acid-sensing ion channel 3 matches the acid-gated current in cardiac ischemia-sensing neurons. PNAS 2001, 98:711-716.
25. Xiong Z.G., Zhu X.M., Chu X.P., Minami M., Hey J., Wei W.L., et al. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 2004, 118:687-698.
26. Tachibana Y., Kurisawa M., Uyama H., Kobayashi S. Thermo- and pH-responsive biodegradable poly(alpha-N-substituted gamma-glutamine)s. Biomacromolecules 2003, 4:1132-1134.
27. Chen M.C., Wong H.S., Lin K.J., Chen H.L., Wey S.P., Sonaje K., et al. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials 2009, 30:6629-6637.
28. Akagi T., Higashi M., Kaneko T., Kida T., Akashi M. Hydrolytic and enzymatic degradation of nanoparticles based on amphiphilic Poly(γ-glutamic acid)-graft-l-phenylalanine copolymers. Biomacromolecules 2006, 7:297-303.
29. Yu D.H., Lu Q., Xie J., Fang C., Chen H.Z. Peptide- conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31:2278-2292.
30. Mi F.L., Tan Y.C., Liang H.F., Sung H.W. In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant. Biomaterials 2002, 23:181-191.
31. Martin C.R., Thomas A.M., Thomas K.H. The future of recombinant growth factors in wound healing. Am J Surg 1998, 176:80S-82S.
32. Pike D.B., Cai S., Pomraning K.R., Firpo M.A., Fisher R.J., Shu X.Z., et al. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 2006, 27:5242-5251.
33. Ho Y.C., Wu S.J., Mi F.L., Chiu Y.L., Yu S.H., Panda N., et al. Thiol-modified chitosan sulfate nanoparticles for protection and release of basic fibroblast growth factor. Bioconjug Chem 2010, 21:28-38.
34. Ho Y.C., Mi F.L., Sung H.W., Kuo P.L. Heparin-functionalized chitosan-alginate polyelectrolyte complex scaffolds for the stabilization and sustained release of basic fibroblast growth factor. Int J Pharm 2009, 376:69-75.
35. Chuang Y.J., Swanson R., Raja S.M., Olson S.T. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem 2001, 276:14961-14971.
36. Kim S.K., Vaishali B., Lee E., Lee S., Lee Y.K., Kumar T.S., et al. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb Res 2006, 117:419-427.
37. Harmer N.J., Ilag L.L., Mulloy B., Pellegrini L., Robinson C.V., Blundell T.L. Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex. J Mol Biol 2004, 339:821-834.
38. Rusnati M., Coltrini D., Caccia P., Dell'Era P., Zoppetti G., Oreste P., et al. Distinct role of 2-O-, N- and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. Biochim Biophys Res Commun 1994, 203:450-458.
39. Erikson A.E., Cousens L.S., Weaver L.H., Matthews B.W. Three dimensional structure of human basic fibroblast growth factor. PNAS 1991, 88:3441-3445.
40. Fromm J.R., Hileman R.E., Caldwell E.E.O., Weiler J.M., Linhardt J.R. Pattern and spacing of basic amino acids in heparin binding sites. Arch Biochem Biophys 1997, 343:92-100.
41. Hung K.W., Kumar T.K.S., Chi Y.H., Chiu I.M., Yu C. Molecular cloning, overexpression, and characterization of the ligand-binding D2 domain of fibroblast growth factor receptor. Biochem Biophys Res Commun 2004, 317:253-258.
42. Spivak-Kroizman T., Lemmon M.A., Dikic I., Ladbury J.E., Pinchasi D., Huang J., et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994, 79:1015-1024.
43. Ishihara M., Shaklee P.N., Yang Z.C., Liang W.S., Wei Z., Stack R.J., et al. Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor. Glycobiology 1994, 4:451-458.
44. Walker A., Turnbull J.E., Gallagher J.T. Specific heparin sulfate saccharides mediated the activity of basic fibroblast growth factor. J Biol Chem 1994, 269:931-935.
45. Peschel D., Zhang K., Aggarwal N., Brendler E., Fischer S., Groth T. Synthesis of novel celluloses derivatives and investigation of their mitogenic activity in the presence and absence of FGF2. Acta Biomaterialia 2010, 6:2116-2125.
46. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64:841-848.